Temasek's investment deepens its exposure to India's pharmaceuticals industry through a company with deepening comparative advantages. The sector is a good proxy for the needs of transforming economies, which is part of Temasek's investment themes.
"ChrysCapital has been a valuable partner for Intas over the years. We are delighted to have lived up to the expectation of ChrysCapital and now look forward to welcoming a globally reputed investor like Temasek to enable Intas to reach greater heights in the years to come," stated Mr Binish Chudgar, vice chairman and managing director of Intas Pharmaceuticals as he announced the sale of the 10.16 percent stake on November, 10, 2014.
Mr Chudgar added further, "In the domestic market, Intas is the 12th largest player in the Indian pharmaceuticals market with a strong chronic oriented portfolio. It is ranked 4th largest in chronic therapy areas with a strong presence in cardiac-diabeto and neuropsychiatry therapeutic segments."
With three decades of progressive strategies, productive R&D, biotechnological expertise and investments in ten advanced manufacturing facilities across the globe, Intas has emerged as one of the fastest growing pharmaceutical organizations in the world.
Mr Sanjiv Kaul, managing director, ChrysCapital said, "Intas has been an excellent investment for ChrysCapital with the company having grown revenues at 27% CAGR since its investment in CY06. Thanks to the promoters and its management team, the shareholders' value has rapidly grown over the last decade, boosted by its strong growth across India and export markets. ChrysCapital reaffirmed its faith in the Company with a fresh INR300 crore investment from a separate fund in CY12 and will continue to remain invested for the next few years."
Over the past few years, Intas has successfully transitioned into a global generics player with over 50 percent of its revenues now coming from international markets. It has a global presence in over 70 countries backed by a strong product basket, pipeline and marketing infrastructure. Presently, US & Europe account for almost 75% of total international revenues and both these geographies continue to exhibit strong growth. The company is investing significant resources to build a pipeline of novel drug delivery technology based products.